share_log

BRIEF-Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma's Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine

reuters ·  Nov 24, 2021 21:24

Nov 24 (Reuters) - Seelos Therapeutics Inc SEEL.O :

* SEELOS THERAPEUTICS ANNOUNCES ACQUISITION OF AN EXCLUSIVE LICENSE OF IX BIOPHARMA'S PROPRIETARY WAFER-BASED DELIVERY PLATFORM FOR SUBLINGUAL KETAMINE

* SEELOS THERAPEUTICS INC - NEW SLS-003 PROGRAM EXTENDS SEELOS' KETAMINE FRANCHISE INTO ADDITIONAL INDICATIONS INCLUDING CHRONIC NEUROPATHIC PAIN

* SEELOS THERAPEUTICS INC - SEELOS PLANS TO EVALUATE SUBLINGUAL KETAMINE, NOW NAMED SLS-003, IN PAIN INDICATIONS

* SEELOS THERAPEUTICS INC - PURSUANT TO LICENSE AGREEMENT, SEELOS WILL PAY IX BIOPHARMA A ONE-TIME, UPFRONT FEE OF $9 MILLION

Source text for Eikon: ID:nPn7sB5Xna Further company coverage: SEEL.O

((Reuters.Briefs@thomsonreuters.com;;))

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment